Biotech and Pharmaceuticals Pharmaceuticals

More

  • rats_200.jpg

    I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day. Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

  • Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks advanced Monday after a better-than-expected reading on the service sector. Plus, investors did some bargain hunting after a two-week decline.

  • If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.

  • US stock index futures pointed higher Monday after two tough weeks for Wall Street.

  • Stocks ended lower Friday as a dismal jobs report capped a string of disappointing economic reports this week, which cast doubt on the recovery. It was the market's second straight down week in which stocks have lost more than 3 percent.

  • Stocks tried to push higher Friday as the dollar's retreat helped the market but investors remained worried about the recovery in the wake of some disappointing economic reports.

  • Stocks opened lower Friday after disappointing reports on jobs and manufacturing.

  • Stock index futures plunged as September nonfarm payroll declines were far worse than Wall Street estimates.

  • Shares of generic drugmaker Mylan dropped for the third straight session yesterday but drew heavy upside options activity.

  • New York Public Information Campaign Warns of Swine Flu

    The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.

  • Sequenom

    It's the equivalent of slipping a press release with negative news under the door at the close of business on a Friday. But after the closing bell on Yom Kippur, when many people including me were trying to give up food and tweeting for a day, Sequenom tossed a grenade.

  • Plus, get calls on Research in Motion, Abbott Labs, gold and more.

  • 2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.

  • Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • dendreon.jpg

    It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.

  • When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.

  • pharma_new3.jpg

    Iin light of evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.